(Reuters) – The
next generation version of Gilead Sciences Inc’s $84,000 hepatitis C
drug, already under fire for its record-breaking costs, is going to be
even more expensive.
Gregg Alton, Gilead’s executive
vice president of corporate and medical affairs, declined to give an
exact price for the new medicine (sofosbuvir + ledipasvir), the first all-oral treatment for the
virus which is expected to launch next month.
total cost of the current treatment is $95,000, which includes Sovaldi
and two older medicines, ribavirin and interferon, according to Gilead.
The price of the new drug would be based on that cost, Alton said in an